CMVLF (Cellectis) FFO


CMVLF Cellectis SA CMVLF
59 GF Score
Price $3.47
GF Value $3.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis FFO?

FFO (Funds from operations) only applies to REITs.

CMVLF
59GF Score
Cellectis SA CMVLF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of $3.47 is trading 4.2% above its estimated GF Value™ of $3.33. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for CMVLF:

  • FFO:
  • GF Value™: $3.33 vs. price of $3.47 (4.2% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score

Get the complete analysis for CMVLF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.33
GF Value